TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immuno-oncology company, announced that President and CEO James A. Bianco, M.D. will participate in a fireside chat at the 4th Annual H.C.

Rhea-AI Summary

TuHURA Biosciences (NASDAQ:HURA), a Phase 3 immuno-oncology company, announced that President and CEO James A. Bianco, M.D. will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference in New York City.

The session is scheduled for Tuesday, May 19, 2026 at 2:00 pm ET, with live and archived webcasts available on TuHURA's investor relations website.

Argus May 12 session

+0.83% close to close Open Argus

Details

News Market Reaction – HURA

In the May 12 session, HURA gained 0.83%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights TuHURA’s participation in an investor conference, adding visibility aro...

Analysis

This announcement highlights TuHURA’s participation in an investor conference, adding visibility around its Phase 3 immuno-oncology programs. In recent months the company secured a $50 million credit facility, updated 2025 financials showing a net loss of $30.1 million, and maintained capital flexibility through a $250,000,000 shelf and ATM program. Investors following this name may focus on cash runway, future financing use under the shelf, and upcoming milestones for IFx‑2.0 and TBS‑2025.

Key Figures

Conference date: May 19, 2026 Credit facility size: $50 million Credit facility interest: 12% annual interest +5 more

Conference date

May 19, 2026

H.C. Wainwright BioConnect Investor Conference presentation date

Credit facility size

$50 million

Revolving credit facility announced on <b>2026-04-22</b>

Credit facility interest

12% annual interest

Loan Agreement with Parkview Holdings One LLC

2025 net loss

$30.1 million

Net loss for year ended December 31, 2025 (10-K/A)

Cash balance

$3.6 million

Cash and cash equivalents as of December 31, 2025

Shelf registration capacity

$250,000,000

Mixed Form S-3 base shelf registered amount

Current share price

$2.40

Price prior to conference news; <b>0.84%</b> up over 24h

Short interest

20.05%

Short interest as a percent of float; days to cover <b>4.72</b>

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Credit facility funding

   24h Move

   +4.1%

   Announced $50M credit facility extending cash runway into 2028.

2. Apr 07

   Management appointment

   24h Move

   +1.7%

   Appointed SVP of Clinical Operations with 20+ years development experience.

3. Apr 01

   Earnings and update

   24h Move

   -9.5%

   Reported 2025 results with $3.6M cash and higher R&D-driven losses.

4. Mar 23

   Clinical leadership move

   24h Move

   +2.1%

   Former JNJ oncology head to lead TBS‑2025 blood cancer program.

5. Feb 27

   Nasdaq compliance

   24h Move

   +3.1%

   Regained compliance with Nasdaq $1.00 minimum bid price requirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

immuno-oncology, cancer immunotherapy, phase 3

3 terms

immuno-oncology medical

"a Phase 3 immuno-oncology company developing novel therapeutics"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

cancer immunotherapy medical

"therapeutics to overcome resistance to cancer immunotherapy"

Cancer immunotherapy is a group of treatments that help the body’s immune system recognize and attack cancer cells, like training the body’s soldiers to spot a hidden enemy. It matters to investors because these therapies can transform patient outcomes and create large markets if shown safe and effective, so clinical trial results, regulatory approvals, and manufacturing scale can drive significant changes in a company’s revenue and stock value.

phase 3 medical

"a Phase 3 immuno-oncology company developing novel therapeutics"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat, at the 4th Annual H.C. Wainwright BioConnect Investor Conference taking place in New York City.

4^th Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 19, 2026
Time: 2:00 pm ET
Links: To register and view presentation, click HERE.

A live and archived webcast of the presentation will also be available through the investors page of TuHURA's corporate website at https://ir.tuhurabio.com/news-events/events.

About TuHURA Biosciences, Inc. 
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA is developing TBS-2025, a VISTA inhibiting mAb moving into Phase 1b/2 in mutNPM1 r/r AML, a molecularly defined subgroup of patients with AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Investor Contact: 
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tuhura-biosciences-to-present-at-the-4th-annual-hc-wainwright-bioconnect-investor-conference-302769078.html

SOURCE TuHURA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will TuHURA Biosciences (NASDAQ:HURA) present at the 4th Annual H.C. Wainwright BioConnect Investor Conference?

TuHURA Biosciences will present on Tuesday, May 19, 2026 at 2:00 pm ET. According to the company, President and CEO James A. Bianco, M.D. will join a fireside chat at the New York City event.

Who is representing TuHURA Biosciences (HURA) at the May 2026 H.C. Wainwright BioConnect Conference?

TuHURA Biosciences will be represented by James A. Bianco, M.D., its President and Chief Executive Officer. According to the company, he will participate in a fireside chat at the investor-focused conference.

How can investors watch TuHURA Biosciences' HURA presentation at the 2026 H.C. Wainwright BioConnect Conference?

Investors can watch via a live and archived webcast available on TuHURA's investor relations website. According to the company, registration and presentation access links are provided through the events section online.

What type of company is TuHURA Biosciences (NASDAQ:HURA) presenting at the May 19, 2026 BioConnect Conference?

TuHURA Biosciences is described as a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy. According to TuHURA, this positioning underpins its participation in investor-focused healthcare conferences.

Where is the 4th Annual H.C. Wainwright BioConnect Investor Conference featuring TuHURA Biosciences held?

The 4th Annual H.C. Wainwright BioConnect Investor Conference will take place in New York City. According to TuHURA Biosciences, its fireside chat with CEO James A. Bianco, M.D. is scheduled there on May 19, 2026.

Will a replay of TuHURA Biosciences' (HURA) May 2026 BioConnect fireside chat be available?

Yes, a live and archived webcast of the TuHURA Biosciences presentation will be available. According to the company, investors can access the replay through the news and events section of its investor relations website.